AMICULUM

At AMICULUM, we harness our diverse expertise and specialist capabilities to activate science and drive transformation of health. Take a look at the video below to see just some of the areas we focus on, spanning the whole product lifecycle 💡 Keep an eye out for upcoming content to learn more about our specialisms and the passion our team members have for their work in all of these areas and more! #HealthcareCommunications #MedComms #HealthcareInnovation

𝗪𝗵𝗮𝘁 𝗱𝗼𝗲𝘀 𝗶𝘁 𝘁𝗮𝗸𝗲 𝘁𝗼 𝗯𝘂𝗶𝗹𝗱 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗮𝗻𝗱 𝗽𝘂𝗯𝗹𝗶𝗰 𝘁𝗿𝘂𝘀𝘁 𝗶𝗻 𝗽𝗵𝗮𝗿𝗺𝗮? This question came up again this week during a great #FTPharma panel discussion on Trust Challenges in Pharma with Michael Elliott (Gilead), Jayasree Iyer (Access to Medicine Foundation), and Seyda Atadan Memis (Takeda). 𝗪𝗵𝘆 𝗶𝘀 𝘁𝗿𝘂𝘀𝘁 𝗶𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁? When trust is low, people are less likely to adhere to long-term treatments or participate in clinical trials—but this is how we innovate and ensure patients receive the best possible care. Patients need to feel confident in the treatments they receive and in the motivations of the companies behind them. 𝗦𝗼, 𝗵𝗼𝘄 𝗱𝗼 𝘄𝗲 𝘀𝘁𝗮𝗿𝘁 𝗯𝘂𝗶𝗹𝗱𝗶𝗻𝗴 𝘁𝗵𝗮𝘁 𝘁𝗿𝘂𝘀𝘁? My takeaways: 👂 𝗟𝗶𝘀𝘁𝗲𝗻 𝘁𝗼 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀, 𝗱𝗼𝗻’𝘁 𝗷𝘂𝘀𝘁 𝘁𝗮𝗹𝗸 𝘁𝗼 𝘁𝗵𝗲𝗺 – go beyond just sharing information. Work with advocacy groups and communities to understand real challenges and patient needs 🔓 𝗔𝗱𝗱𝗿𝗲𝘀𝘀 𝗺𝗶𝘀𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝘁𝗿𝗮𝗻𝘀𝗽𝗮𝗿𝗲𝗻𝗰𝘆 – being transparent about why medicines are developed the way they are (pricing, research processes) and who they’re meant to help, can close the trust gap. Give patients and the public the clear information they need to make an informed decision 🔑 𝗜𝗺𝗽𝗿𝗼𝘃𝗲 𝗮𝗰𝗰𝗲𝘀𝘀 𝘁𝗼 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁. Patients want treatments that are not only effective but accessible and fair Having partnered with patients and advocates – the lived-experience experts - in designing studies, building communication strategies, and co-authoring research, key words for me when building trust are patient 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽 and 𝘁𝗿𝗮𝗻𝘀𝗽𝗮𝗿𝗲𝗻𝗰𝘆. When patients are included and informed, we can all make empowered decisions, improve medication adherence and clinical trial participation. #PatientEngagement #Pharma #HealthEquity #ClinicalTrials #PatientAdherence #PatientAdvocacy #TrustInHealthcare #LinkedInLive #FTLive

"Time to turn toys into tools" (quote from @RohitAlimchandani, Cognizant, at a FT Pharma fireside chat) Pharma's reaction so far to the digital innovation appears to have fallen into two camps, categorized as the 'Laggards' and the 'Leaders' by Rohit during his FT Pharma fireside chat earlier today. The Laggards – those that haven't truly engaged with the the digital journey and have tinkered with AI in a siloed and scattergun approach. The Leaders – those visionaries that have taken a strategic enterprise view to building a platform for use across their Co (take Pfizer, for example). To the laggards, the time for tinkering with AI is over. If you don't catch up , you are going to fall by the wayside. The rate of digital innovation is accelerating and you need to keep up. We've always known (feared) that AI is here to steal our jobs, but I thought this was going to impact administrators, content developers, etc, and that we would all end up with new roles checking that the AI hasn't gone rogue. Interestingly, Cognizant has started hiring fine arts graduates as prompt engineers, because it has found that data scientists aren't that good at looking at the world and describing it – I didn't see that coming. So what about the future? Proliferation of agentic AI (versus the currently more commonly implemented autonomous systems) will lead to the commoditization of intelligence (ie virtual PhD-level expertise at your fingertips). I'm off to educate myself on the Dutch Renaissance masters! #FTPharma #AI #johannesvermeer

I joined the session at #FTLive this morning where Emma Walmsley was being interviewed, and for me, a strong theme from the discussion was trust. Our industry has always had a difficult time building trust despite the stringent compliance environment and strict regulations we work within. It made me think, what are the best ways are to build that trust with the many different stakeholders we engage with? Emma highlighted transparency as key, and this is certainly part of it, but I think there's more we need to consider. When it comes to building trust, it's not just WHAT we say and do but HOW. Are robust data enough to speak for themselves? It doesn't seem so, but when we try to layer messaging onto the data to tell a story it can be viewed as 'spin'. Are actions what will make the difference? Emma talked about GSK's commitment to make medications available to as many people living with HIV in Africa as possible, a great initiative but there can still be cynicism about these endeavors. Trust is a particularly pertinent topic today, as we think about a new wave of international relations, but it's something that's fundamental to everything we do. As Emma said, healthcare is a particularly sensitive area with all of it's emotional and personal aspects, after all our health is the most valuable thing we all have as individuals, so how we talk about it matters. Perhaps the best way to earn trust as an industry is to start with truly listening. We need to really understand what people want, and how that differs, and use that to drive our strategies and to tailor communications. Working together as a healthcare community is also key, let's support each other to get vaccines and medicines to the people who need them most by creating connections based on trust! #FTPharma #trust #insights #pharma #healthcare

“Companies that do early deals tend to be more viable than those that don’t.”   This take-home from an interesting session on dealmaking and financing at today’s FT Global Pharma and Biotech Summit hit a chord. Not every pharma or biotech will be viable. Think about that for a moment. In this fiendishly complex pharmaceutical ecosystem that we work in, we tend to think about the success stories more than the failures, but failures indeed there are. As the panel also noted, “We don’t hear much about the companies that go insolvent, those stories don’t make good news”. An interesting if slightly sobering perspective. So what can we do to help? Well there are many factors behind success and failure, but one area I can see where there is an obvious opportunity for helping de-risk portfolio and investment decisions is the humble landscape analysis. Investing more here, early on, on either the buy or sell side, won’t guarantee solvency, but it should certainly help! Contact me to learn more. https://lnkd.in/eVaGSeJc #FTPharma #AMICULUM #strategy #landscapeanalysis

Are you attending #ISPOR2024? Stop by booth #1323 to meet Claire Woon, Manca Povsic, Frank Fisher, and Kuljeet Sohanpal from AMICULUM. Our team will also be presenting 3 posters: ▪ Switching treatments in psoriasis: A targeted literature review ▪ How is climate change affecting the spread of vector-, water-, and food-borne diseases? ▪ European health technology regulation and AI: Are new regulations driving the adoption of AI in joint clinical assessment development? Check out our latest blog for more details: https://loom.ly/8UPnQPs #MarketAccess #EvidenceGeneration #JCA

We have a packed agenda of events and congresses lined up in November and we can't wait! Are you attending any of these? Let us know in the comments below 👇 Reuters Events Pharma FT Live Evidence Life Science ISPOR—The Professional Society for Health Economics and Outcomes Research Global Insight Conferences #REcustomerEU24 #FTPharma #MedAffairs #ISPOREurope

The countdown to #ISPOREurope 2024 is on! Whether you’re navigating complex market access challenges or looking for expert insights, our team, Manca Povsic, Claire Woon, and Frank Fisher, will be at AMICULUM booth #1323 ready to answer any questions you have about how we can support your needs. See you in Barcelona! #MarketAccess #EvidenceGeneration #JCA

#MedAffairs #Transformation - 16th Annual – F2F conference #Zürich! Thank you to our event partner AMICULUM! Join Stephen Wilson’s session and understand what capabilities can accelerate medical affairs into the future @ our MedAffairs Transformation live conference! Program available: https://lnkd.in/d6VqUMcA #medaffairs #medicalaffairs #insights #KOL #engagement #communication #evidencelifescience

Claire Woon shines a light on AMICULUM’s market access and HEOR offering and shares her perspectives on key access developments – click through the carousel to find out more! #MarketAccess #HEOR #JCA